Depression Clinical Trial
Official title:
A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline.
Study Introduction:
Major depressive disorder (MDD) is a global health disease associated with significant
morbidity and costs. Many anti-depressants exist within the monoaminergic system yet novel
therapeutics are still needed outside of this system. Ezogabine, currently approved by the
FDA for adjunctive treatment of partial-onset seizures, may serve as a potential key agent
for those with MDD. Ezogabine is known to bind to and activate KCNQ transmembrane K+ ion
channels, specifically targeting KCNQ2 in the VTA. Such membrane activity has been show to
play a role in previous studies involving a social defeat model of depression. Specifically,
data has shown that KCNQ channels were upregulated only in resilient mice and moreover,
ezogabine was able to potentiate KCNQ channel activity to result in a fast reversal of the
depressed phenotype.
General Investigational Plan:
Objectives:
A. Primary Efficacy Objective: To test the antidepressant effects of Ezogabine in MDD.
B. Primary Safety Objective: To characterize the safety and tolerability of Ezogabine in
patients with MDD.
C. Secondary Objectives: To measure the effects of Ezogabine on ventral tegmental area
(VTA)-striatal reward circuitry in MDD using reward task-based functional MRI. Rationale:
Ezogabine is hypothesized to modulate the firing rate of VTA dopamine (DA) neurons and
thereby influence the functioning of the mesolimbic reward system.
Hypotheses
A. Efficacy Hypothesis:
Hypothesis 1a: Depressive symptoms will be significantly decreased following an 8-week
treatment period compared to baseline, as measured by change in Montgomery-Åsberg Depression
Rating Scale (MADRS).
Hypothesis 1b: The antidepressant response rate at study end (defined as 50% in depressive
symptoms compared to baseline) will exceed 50%, consistent with known response rates of
current antidepressant agents.
B. Safety Hypothesis: Ezogabine will be safe and adverse event rates will be similar to rates
observed in other adult populations. Specific safety items to be monitored include frequency
and intensity of adverse events as measured by the Patient Rated Inventory of Side Effects
(PRISE) and treatment-emergent suicidal ideation or behavior as measured by the
Columbia-Suicide Severity Rating Scale (C-SSRS).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |